2025/02/13 by Oliver A. Cornely, Rosanne Sprute, Matteo Bassetti +97 · 1 voice · 5 citations
Medicine · #Antifungal resistance and susceptibility #Fungal Infections and Studies #Pneumocystis jirovecii pneumonia detection and treatment
paper · doi:10.1016/s1473-3099(24)00749-7
openalex publication_date 2025/02/13 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/03
Candida species are the predominant cause of fungal infections in patients treated in hospital, contributing substantially to morbidity and mortality. Candidaemia and other forms of invasive candidiasis primarily affect patients who are immunocompromised or critically ill. In contrast, mucocutaneous forms of candidiasis, such as oral thrush and vulvovaginal candidiasis, can occur in otherwise healthy individuals. Although mucocutaneous candidiasis is generally not life-threatening, it can cause considerable discomfort, recurrent infections, and complications, particularly in patients with underlying conditions such as diabetes or in those taking immunosuppressive therapies. The rise of difficult-to-treat Candida infections is driven by new host factors and antifungal resistance. Pathogens, such as Candida auris (Candidozyma auris) and fluconazole-resistant Candida parapsilosis, pose serious global health risks. Recent taxonomic revisions have reclassified several Candida spp, potentially causing confusion in clinical practice. Current management guidelines are limited in scope, with poor coverage of emerging pathogens and new treatment options. In this Review, we provide updated recommendations for managing Candida infections, with detailed evidence summaries available in the appendix.